FORM 4

Check this box if no longer subject

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DС	20549
vvasimigton,	D.O.	20040

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response 0.5

				or Se	ction 30(h	ı) of the	e Inves	stmen	t Company A	ct of 194	10				
1. Name and Address of Reporting Person* <u>Control Empresarial de Capitales S.A. de</u> <u>C.V.</u>			2. Issuer Name and Ticker or Trading Symbol PROKIDNEY CORP. [PROK]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title V Other (specify					
(Last)	/Eir	oot) (A	Aiddlo)	3. Date of Earliest Transaction (Month/Day/Year) 03/13/2024							below) Add'l Rep. Persons-see Ex.99-1				
(Last) (First) (Middle) PASEO DE LAS PALMAS 781, PISO 3 LOMAS DE CHAPULTEPEC			4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street) CIUDAD DE MEXICO O5 11000			Rul	Form filed by More than One Reporting Person Rule 10b5-1(c) Transaction Indication											
(City) (State) (Zip)				Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											
		Table	I - Non-Deriva	tive S	Securiti	es Ad	cquir	red,	Disposed	of, or	Benefici	ally Own	ed		
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Yea	2A. Deemed Execution Date if any (Month/Day/Yea		n Date, Tr		ction Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						(Code	v	Amount	(A) or (D)	Price	(Instr. 3 a		(man. 4)	(111311. 4)
	Ordinary Sh 9.1 hereto)	ares (as defined	in 03/13/2024				P		50,000	A	\$1.5018(1	63,168,	645(6)(7)(8)	D ⁽⁹⁾	
	Ordinary Sh 9.1 hereto)	ares (as defined	in 03/14/2024				P		50,000	A	\$1.3585(2	63,218,	645(6)(7)(8)	D ⁽⁹⁾	
	Ordinary Sh 9.1 hereto)	ares (as defined	in 03/20/2024				P		33,000	A	\$1.3973(3	63,251,	645(6)(7)(8)	D ⁽⁹⁾	
	Ordinary Sh 9.1 hereto)	ares (as defined	in 03/22/2024				P		14,000	A	\$1.399(4)	63,265,	645(6)(7)(8)	D ⁽⁹⁾	
	Ordinary Sh 9.1 hereto)	ares (as defined	in 03/25/2024				P		30,000	A	\$1.4318(5	63,295,	645(6)(7)(8)	D ⁽⁹⁾	
		Tab	ole II - Derivati						isposed o				d		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (I 8)	5. ction of Instr. De Se Ac (A Di	Numbe	e (Mes	Date E	Exercisable an on Date Day/Year)	d 7. 1 Am Sec Und Der Sec	Fitle and count of curities derlying rivative curity (Instr. and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$1.4900 to \$1.5018 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

Date

ànd 5)

(A) (D)

Code

Title

Expiration

Amount or Number

Shares

- 2. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$1.3550 to \$1.3600 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote (2) to this Form 4
- 3. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$1.3890 to \$1.4000 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote (3) to this Form 4
- 4. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$1.3800 to \$1.4000 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
- 5. Weighted average price. These shares were sold in multiple transactions at prices ranging from \$1.4300 to \$1.4399 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
- 6. Includes 63,118,645 Class B Ordinary Shares, \$0.0001 par value per share (the "Class B Ordinary Shares"), each of which has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the SEC on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis. The reporting person beneficially owns 63,118,645 Common Units.
- 7. Excludes 6,999,999 Earnout Rights received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"). Pursuant to the earnout provisions of the Business Combination Agreement, the reporting person is entitled to receive earnout restricted Common Units ("Earnout RCUs") and earnout restricted Class B Ordinary Shares ("Earnout RSRs" and together with the Earnout RCS, the "Earnout Rights") that vest in three equal tranches based on the achievement of share price milestones set forth in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnote (6) above, may be exchanged for Class A Ordinary Shares at the election of the reporting person.
- 8. One-third of the Earnout Rights will vest upon the volume weighted average price ("VWAP") of a Class A Ordinary Share reaching \$15.00 per share for any 20 trading days over any consecutive 30 day trading period, an additional one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching \$20.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching \$25.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching \$25.00 per share for any 20 trading days over any consecutive 30 day trading period, in each case, such share price milestone must be achieved by the fifth anniversary of the closing of the transactions contemplated by the Business Combination Agreement.
- 9. See attached Exhibit 99.1 to this Form 4, which is hereby incorporated herein by reference

<u>/s/ MARCO ANTONIO SLIM</u>
<u>DOMIT, ATTORNEY-IN-</u> <u>05/16/2024</u>
<u>FACT</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Name and Address of Additional Reporting Persons:

Mr. Carlos Slim Helú, Mr. Carlos Slim Domit, Mr. Marco Antonio Slim Domit, Mr. Patrick Slim Domit, Ms. María Soumaya Slim Domit, Ms. Vanessa Paola Slim Domit and Ms. Johanna Monique Slim Domit (collectively, the "Slim Family"), each with the following address:

Paseo de Las Palmas #736 Colonia Lomas de Chapultepec 11000 Ciudad de México, México

Explanation of Responses:

Beneficial Ownership

As of the date of this filing, (i) Control Empresarial de Capitales S.A. de C.V. ("Control Empresarial") owns 63,295,645 shares of Class A Ordinary Stock, \$0.0001 par value per share (the "Class A Ordinary Shares") and (ii) the Slim Family, which are beneficiaries of a Mexican trust that in turn owns all of the issued and outstanding voting equity securities of Control Empresarial, may be deemed to beneficially own indirectly the Class A Ordinary Shares beneficially owned by Control Empresarial constitute approximately 27.3% of the 231,698,039 total shares issued and outstanding, comprising 63,923,230 Class A Ordinary Shares and 167,774,809 Class B Ordinary Shares, \$0.0001 par value per share (the "Class B Ordinary Shares"), as reported in the Form 10-Q filed by the Issuer with the Securities and Exchange Commission ("SEC") on May 10, 2024. As a result, the Slim Family may also be deemed to beneficially own approximately 27.3% of the 231,698,039 total shares issued and outstanding, comprising 63,923,230 Class A Ordinary Shares and 167,774,809 Class B Ordinary Shares, as reported in the Form 10-Q filed by the Issuer with the SEC on May 10, 2024.

Signature Page

Carlos Slim Helú	
Carlos Slim Domit	By: /s/ Marco Antonio Slim Domit
	Marco Antonio Slim Domit
Marco Antonio Slim Domit	Attorney-in-Fact*
	May 16, 2024
Patrick Slim Domit	7
María Soumaya Slim Domit	7
,	
Vanessa Paola Slim Domit	7
Johanna Monique Slim Domit	7
1	
CONTROL EMPRESARIAL DE CAPITALES S.A.	
DE C.V.	
By: Víctor Manuel Gutierrez Lopez	7
Title: Attorney-in-Fact	

^{*} See the Powers of Attorney for the members of the Slim Family and Control Empresarial, which are filed as exhibits to the Schedule 13D/A filed by the Slim Family and Control Empresarial with the SEC on February 3, 2022 in connection with their beneficial ownership of American Depositary Shares, each representing 20 Series L Shares of América Móvil, S.A.B. de C.V., are hereby incorporated herein by reference.